Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 19;17:61. doi: 10.1186/s12906-017-1559-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Trial flow & study design. General information = age, sex, weight, time when symptoms emerge, time when diagnosed, anti-SSA antibodies, abnormal Schirmer test results, decreased unstimulated salivary flow, previous systemic involvement, previous treatment with another immunosuppressant, current systemic involvement. 1st outcome = numeric analog scale (NAS) (Dryness, Pain and Fatigue). 2nd outcome = EULAR Sjogren Syndrome Patient Reported Index (ESSPRI), EULAR Sjogren Syndrome Disease Activity Index (ESSDAI), Medical Outcome Study Short From 36 Short-Form Health Survey (SF-36), Hospital Anxiety and Depression (HAD), Serum Immunoglobulin (IgG), IgA and IgM, Schirner test score and unstimulated salivary flow, salivary glands untrasounds